ILCA warmly thanks all Partners and Sponsors for their unrestricted support to the 2014 Annual Conference and their commitment to help advance liver cancer science.

Diamond Partner


Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Silver Partner


Celsion is fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer.

The pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlasTM, TheraSilenceTM and RASTTM. For more information on Celsion, visit our website.

Pre-Conference Workshop Partner


A phase 3, randomized, double-blind study of tivantinib (ARQ 197) in subjects with MET-High, Child-Pugh A, ECOG 0-1, inoperable, measurable hepatocellular carcinoma (HCC) who progressed or were intolerant to one prior systemic therapy including sorafenib.

Coffee Break Sponsors


Media Partners